National Practice Patterns and Outcomes for T4b Urothelial Cancer of the Bladder

被引:21
|
作者
Haque, Waqar [1 ]
Verma, Vivek [2 ]
Butler, E. Brian [3 ]
Teh, Bin S. [3 ]
机构
[1] Greater Houston Phys Med Assoc, Dept Radiat Oncol, Houston, TX USA
[2] Univ Nebraska Med Ctr, Dept Radiat Oncol, Omaha, NE USA
[3] Houston Methodist Hosp, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
Bladder cancer; Chemoradiation; Chemotherapy; Cystectomy; Radiation therapy; RADICAL CYSTECTOMY; DATA-BASE; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; SURVIVAL; CARCINOMA; CARE; THERAPY;
D O I
10.1016/j.clgc.2017.08.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The National Cancer Data Base was queried (2004-2013) for patients diagnosed with T4b bladder cancer. A total of 896 patients were observed. Patients treated with definitive chemoradiation or radical cystectomy were observed to have the highest overall survival. Purpose: Management of cT4b bladder cancer is poorly defined; national guidelines recommend chemotherapy (CT) alone or chemoradiation (CRT). Using a large, contemporary dataset, we evaluated national practice patterns as well as associated outcomes, especially with respect to radical cystectomy (RC) and CRT versus CT alone. Methods: The National Cancer Data Base was queried (2004-2013) for patients diagnosed with cT4bN0-3M0 bladder cancer. Patients were divided into 5 treatment groups: CT alone, CRT, RC (with/without CT/radiotherapy [RT]), other treatment (subtherapeutic RT with/without CT), or no treatment. Statistics included multivariable logistic regression to determine factors predictive of observation, Kaplan-Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS. Results: Of 896 total patients, 185 (20.6%) underwent CT alone, 80 (8.9%) CRT, 161 (18.9%) RC, 221 (24.7%) other treatments, and 249 (27.8%) observation. Differences in treatment paradigms were appreciated based on age, gender, nodal status, insurance, and facility-related parameters. Observation yielded a median OS of 3.7 months, lower than CT alone (P < .001). As compared with the latter, CRT was associated with higher OS (10.5 vs. 12.1 months, P = .004). RC-based treatment displayed the numerically highest OS (14.2 months) and was statistically similar to CRT (P = .676). Treatment with any modality independently predicted for superior OS over observation. Conclusions: In the largest study of its kind, a surprisingly high proportion of patients underwent observation. CRT is associated with higher survival over CT alone, and carefully selected patients undergoing RC may experience prolonged survival. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:42 / +
页数:9
相关论文
共 50 条
  • [1] Management of Unresectable T4b Esophageal Cancer Practice Patterns and Outcomes From the National Cancer Data Base
    Cushman, Taylor R.
    Shaaban, Sherif G.
    Moreno, Amy C.
    Lin, Chi
    Verma, Vivek
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (02): : 154 - 159
  • [2] The role of radical cystectomy in patients with clinical T4b bladder cancer
    Black, Peter C.
    Dinney, Colin P. N.
    Brown, Gordon A.
    Kassouf, Wassim
    Siefker-Radtke, Arlene O.
    Munsell, Mark F.
    Grossman, H. Barton
    Kamat, Ashish M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (02) : 157 - 161
  • [3] Comparison of Long-Term Survival Outcomes of T4a and T4b Colorectal Cancer
    Lim, Ji Ha
    Huh, Jung Wook
    Lee, Woo Yong
    Yun, Seong Hyeon
    Kim, Hee Cheol
    Cho, Yong Beom
    Park, Yoon Ah
    Shin, Jung Kyong
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [4] Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?
    Moschini, Marco
    Zamboni, Stefania
    Mattei, Agostino
    Baumeister, Philipp
    Di Bona, Carlo
    Cornelius, Julian
    Shariat, Shahrokh F.
    Freschi, Massimo
    Zaffuto, Emanuele
    Salonia, Andrea
    Montorsi, Francesco
    Briganti, Alberto
    Colombo, Renzo
    Gallina, Andrea
    San Raffaele, Ospedale
    UROLOGIA INTERNATIONALIS, 2019, 102 (03) : 269 - 276
  • [5] Definitive chemoradiotherapy for clinical T4b esophageal cancer - Treatment outcomes, failure patterns, and prognostic factors
    Huang, Tzu-Ting
    Li, Shau-Hsuan
    Chen, Yen-Hao
    Lu, Hung-, I
    Lo, Chien-Ming
    Fang, Fu-Min
    Chou, Shang-Yu
    Chiu, Yi-Chun
    Chou, Yeh-Pin
    Wang, Yu-Ming
    RADIOTHERAPY AND ONCOLOGY, 2021, 157 : 56 - 62
  • [6] Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population
    Ghate, Ketan
    Brennan, Kelly
    Karim, Safiya
    Siemens, D. Robert
    Mackillop, William J.
    Booth, Christopher M.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 (01) : 136 - 142
  • [7] Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data Base
    Haque, Waqar
    Verma, Vivek
    Butler, E. Brian
    Teh, Bin S.
    BLADDER CANCER, 2017, 3 (04) : 283 - 291
  • [8] Treatment patterns and survival in T4b esophageal cancer: a retrospective cohort study
    Yu, Bin-Bin
    Huang, Jiang-Qiong
    Liang, Huan-Wei
    Liu, Yang
    Chen, Long
    Pei, Su
    Huang, Wei
    Pan, Xin-Bin
    AGING-US, 2024, 16 (08): : 7131 - 7140
  • [9] Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?
    Booth, Christopher M.
    Karim, Safiya
    Brennan, Kelly
    Siemens, David Robert
    Peng, Yingwei
    Mackillop, William J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (03) : 89.e13 - 89.e20
  • [10] National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013
    Bateni, Zhoobin H.
    Pearce, Shane M.
    Zainfeld, Daniel
    Ballas, Leslie
    Djaladat, Hooman
    Schuckman, Anne K.
    Daneshmand, Siamak
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (03): : 343 - 350